Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 11/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.35 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568485 | 0.89 | NEK1 (0.38) | NEK1PDPK1 | |
| SCHEMBL23327628 | 0.83 | NEK1 (0.38) | NEK1GPR35MAP2 | |
| SCHEMBL20569867 | 0.81 | GPR35 (0.39) | NEK1GPR35 | |
| SCHEMBL30794689 | 0.81 | KDM4E (0.53) | GPR35MAP2 | |
| SCHEMBL20569212 | 0.80 | NEK1 (0.32) | NEK1GPR35 | |
| SCHEMBL23327820 | 0.79 | NEK1 (0.32) | NEK1GPR35 | |
| SCHEMBL20568180 | 0.78 | GPR35 (0.50) | NEK1GPR35 | |
| SCHEMBL20568482 | 0.74 | BRAF (0.36) | GPR35MAP2GPR17GRIN1 | |
| SCHEMBL20568373 | 0.71 | GPR35 (0.35) | NEK1GPR35 | |
| SCHEMBL20568483 | 0.71 | PRKCZ (0.33) | NEK1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | claimed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | claimed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, LCT | NEK1 3363/4885PDPK1 2475/4885GPR35 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.